Javascript must be enabled to continue!
Preparation iiand characterization of mucoadhesive microcapsules of paclitaxel
View through CrossRef
The objective of the present work was to develop paclitaxel encapsulated mucoadhesive microcapsules with an aim to enhance its efficacy and control the drug release in cancer patients. Paclitaxel microcapsules with a coat consisting of sodium alginate and mucoadhesive polymer such as acacia, Carbomer 941, Povidone K-30, Macrogol (PEG 6000) were prepared by ionotropic gelation technique and were evaluated for morphological characters, drug content, loading efficiency, drug–polymer interactions, swelling ratio, mucoadhesive properties and in vitro drug release. The resulting microcapsules were discrete, spherical, and free-flowing with a particle size range of 534 to 822 µm. The microencapsulation efficiency was 45.09–99.83%. The microcapsules prepared with alginate along with macrogol (F4M) have exhibited good mucoadhesive property in the in vitro wash off test. The swelling ratio of microcapsules was enhanced with increased alginate concentration and the formulation (F4) showed highest swelling index of 2666. Paclitaxel release from these mucoadhesive microcapsules was slow and extended over a period of 6 h and further depends upon the concentration of the alginate. The percent drug release of alginate-acacia microcapsules (F4Ac) was higher than other formulations in the present study. In conclusion, alginate-acacia mucoadhesive microcapsules could be promising vehicle for oral controlled release of paclitaxel.
Title: Preparation iiand characterization of mucoadhesive microcapsules of paclitaxel
Description:
The objective of the present work was to develop paclitaxel encapsulated mucoadhesive microcapsules with an aim to enhance its efficacy and control the drug release in cancer patients.
Paclitaxel microcapsules with a coat consisting of sodium alginate and mucoadhesive polymer such as acacia, Carbomer 941, Povidone K-30, Macrogol (PEG 6000) were prepared by ionotropic gelation technique and were evaluated for morphological characters, drug content, loading efficiency, drug–polymer interactions, swelling ratio, mucoadhesive properties and in vitro drug release.
The resulting microcapsules were discrete, spherical, and free-flowing with a particle size range of 534 to 822 µm.
The microencapsulation efficiency was 45.
09–99.
83%.
The microcapsules prepared with alginate along with macrogol (F4M) have exhibited good mucoadhesive property in the in vitro wash off test.
The swelling ratio of microcapsules was enhanced with increased alginate concentration and the formulation (F4) showed highest swelling index of 2666.
Paclitaxel release from these mucoadhesive microcapsules was slow and extended over a period of 6 h and further depends upon the concentration of the alginate.
The percent drug release of alginate-acacia microcapsules (F4Ac) was higher than other formulations in the present study.
In conclusion, alginate-acacia mucoadhesive microcapsules could be promising vehicle for oral controlled release of paclitaxel.
Related Results
Development, characterization and optimization of polymeric mucoadhesive microcapsules containing anticancer agent using response surface method: in vitro and in vivo study
Development, characterization and optimization of polymeric mucoadhesive microcapsules containing anticancer agent using response surface method: in vitro and in vivo study
The present research work covenants the preparation, characterisation and optimisation of mucoadhesive microcapsules containing paclitaxel through ionic gelation method using 32 st...
Abstract 1071: Efficacy of targeted osmotic lysis using pulsed electric field stimulation compared to paclitaxel for treating murine, triple-negative breast carcinoma
Abstract 1071: Efficacy of targeted osmotic lysis using pulsed electric field stimulation compared to paclitaxel for treating murine, triple-negative breast carcinoma
Abstract
Targeted osmotic lysis (TOL), the concurrent stimulation of voltage-gated sodium channels (VGSCs) and blockade of Na+ pumps, kills up to 100% of highly mali...
Abstract 1849: Determining the molecular requirements for paclitaxel-induced spindle multipolarity
Abstract 1849: Determining the molecular requirements for paclitaxel-induced spindle multipolarity
Abstract
Paclitaxel (TaxolTM) and other microtubule poisons are standard chemotherapy agents used in the treatment of breast cancer. However, only a subset of patien...
Abstract A186: Low dose paclitaxel treatment increase the stability of p27Kip1
Abstract A186: Low dose paclitaxel treatment increase the stability of p27Kip1
Abstract
The purpose of our study is to better understand how taxanes (paclitaxel, docetaxel) induce cell death. Taxanes play a critical role in combination chemothe...
Preparation and barrier properties of the microcapsules added nanoclays in the wall
Preparation and barrier properties of the microcapsules added nanoclays in the wall
AbstractPreparation of microcapsules applied to the fabrication of self‐healing composites has attracted a lot of attention. However, the leakage of core material from the microcap...
Delayed hypersensitivity and cytokine release syndrome to paclitaxel and nab-paclitaxel: a case report
Delayed hypersensitivity and cytokine release syndrome to paclitaxel and nab-paclitaxel: a case report
Hypersensitivity reactions (HSRs) to paclitaxel, particularly those mediated by the solubilizer Cremophor® EL, are common, occurring in approximately 10% of patients despite premed...
Preparation and Characterization of Microencapsulated Ethylenediamine with Epoxy Resin for Self-healing Composites
Preparation and Characterization of Microencapsulated Ethylenediamine with Epoxy Resin for Self-healing Composites
AbstractHealing agent microcapsules have been used to realize self-healing for polymeric composites. In this work a novel kind of microcapsules encapsulating ethylenediamine (EDA) ...
Abstract 1844: Centriole amplification sensitizes cells to paclitaxel
Abstract 1844: Centriole amplification sensitizes cells to paclitaxel
Abstract
Paclitaxel (Taxol) is a widely utilized treatment for primary and metastatic breast cancer. However, only about 50% of patients respond and no predictive bi...

